A Review of Chinese Herbal Medicine for the Treatment of Chronic Heart Failure

Yong Wang1,#, Qiyan Wang1,#, Chun Li2, Linghui Lu3, Qian Zhang1, Ruixin Zhu4,5,* and Wei Wang3,*

1School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China; 2Modern Research Center for Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China; 3Basic Medical College, Beijing University of Chinese Medicine, Beijing 100029, China; 4Department of Bioinformatics, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China; 5School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, Liaoning, China

Abstract: Heart failure is one of the major causes of mortality worldwide and it is the end stage of several cardiovascular diseases. Traditional Chinese medicine has been used in the management of heart failure for a long time. Only until recently, well-designed clinical trials have been put into practice to study the efficacies of Chinese herbs. Extensive studies have also been carried out to explore the underlying mechanisms of pharmaceutical actions of Chinese herbs. In this study, we will summarize the frequently used Chinese herbs, formulae and patent Chinese drugs in treating patients with heart failure and review published clinical evaluations of Chinese herbs in treating cardiovascular diseases. The mechanisms by which Chinese herbs exert cardio-protective effects will also be reviewed. In the end, we will point out the limitations of current studies and challenges facing modernization of traditional Chinese medicine.

Keywords: Heart failure, Chinese herbs, clinical evaluation, mechanism studies, Chinese medicine, cardiovascular diseases.

1. INTRODUCTION
Heart failure (HF), as the final stage of cardiac diseases, is an abnormality of cardiac structure or function. Several diseases, including coronary heart disease (CHD), acute myocardial infarction (AMI), high blood pressure, and different kinds of cardiomyopathy, can lead to heart failure [1, 2]. Patients with HF have compromised blood supply as the failing heart is unable to pump sufficiently [3]. According to treatment guidelines, the conventional therapeutic approaches in HF management are angiotensin-converting enzyme inhibitors (ACEIs), β-adrenergic blockers, and diuretics [4, 5]. However, prolonged uses of these chemical drugs may lead to severe side effects, including electrolyte depletion, fluid depletion, hypotension, etc. [6-8]. Therefore, traditional Chinese medicine (TCM) has been considered as an alternative therapeutic strategy for the treatment of chronic heart failure (CHF) with lower cost and fewer side effects.

Combining disease with syndrome is an important treatment principle in TCM clinical practice. Generally, syndrome, which is originated from TCM, is a summary of the pathological status that describes severity and stages of the diseases and the patient’s individual reaction. Syndrome differentiation is conducted based on the information collected through four traditional diagnostic methods including inspection, listening and smelling examination, inquiry and palpation, and it is also used as the guidance for prescription principle. The top six syndromes of patients with heart failure are yang deficiency, qi deficiency, blood stasis, water retention, yin deficiency and turbid phlegm [9, 10]. Blood stasis is found to be the main syndrome element of heart disease, followed by qi deficiency [11]. According to TCM theory, the heart governs mental activities (shen). The heart qi maintains blood circulation, whereas heart yang promotes fluid metabolism. The fundamental dysfunction in heart failure is the long period of deficiency in heart qi and yang, which consequently lead to stasis of blood circulation [12]. Therefore, the treatment principles are that they collectively benefit the qi and warm yang of the heart, specifically by activating blood circulation to dissipate blood stasis and disperse swelling.

Concept of TCM prescriptions is to integrate several medicinal herbs according to syndrome differentiation to form a “formulae” (Fufang). The well-accepted theory of TCM is “Jun-Chen-Zuo-Shi”. "Jun" (the emperor) cures the main causes or symptoms of the disease; "Chen" (minister) strengthens the effect of “Jun”, or treats accompanying symptoms; the main function of "Zuo" (adjuvant) is to reduce or eliminate potential toxic effects of the Jun or Chen herbs, whereas “Shi” (courier) delivers the above herbs to target organs [13]. A number of formulae have been prescribed widely in the treatment of heart failure and several patent drugs (including pills, capsules and injections) have been manufactured by pharmaceutical companies. Exploiting the active components of formulae and investigating the pharmacological actions of TCM have been an ongoing effect in understanding the mechanisms of TCM. Some previous studies have reviewed the effects or the underlying mechanism of some TCM in treating cardiovascular diseases [14-23]. In this review, we will summarize the commonly prescribed Chinese herbs, the clinical evaluations of TCM and the progress made in understanding the mechanisms of TCM in treating cardiovascular diseases and HF.

2. COMMONLY PRESCRIBED TCM IN THE TREATMENT OF HF
Chinese herbs have different properties and therapeutic nature. According to TCM theory, cold and cool herbs belong to yin, whereas hot and warm herbs belong to yang. Balancing yin and yang in the body is vital for maintaining health. Chinese herbs have been used for the effective treatment of heart failure for thousands of years. The commonly prescribed herbs for treating different heart failure syndromes are as follows: Radix aconiti carmichaeli (Fuzi), Atractylodes (Baizhu), Cassia twig (Guizhi), Dried ginger (Ganji-

#These authors contributed equally to this work.
As mentioned above, it is a common practice that several herbs with different amounts are prescribed together, as a formula or “Fufang” in Chinese, to enhance the therapeutic efficacies of each herb and reduce toxicities. There are several most commonly prescribed formulae that have been proven effective clinically for the treatment of heart failure [24-27]. These decoctions prescribed by physicians include: Zhenwu tang, Shengmai san, Baoyuan tang, Xuefuzhuyu tang, etc. [10].

### Table 1. Commonly prescribed formulae and patent drugs in the treatment of heart failure.

| Form                          | Name                        | Components                                               |
|-------------------------------|-----------------------------|----------------------------------------------------------|
| Formulae prescribed by physicians | Baoyuan Tang               | Renshen, Huangqi, Gancao, Rougui                         |
|                               | Danshen Yin                | Danshen, Tanxiang, Sharen                                |
|                               | Shengmai San               | Renshen, Maidong, Wuwei                               |
|                               | Taohongsiwu Tang           | Danshen, Shudi, Chuangxiong, Baishao, Taoren, Honghua    |
|                               | Tinglidazaoxiefei Tang     | Tingli, Dazao                                           |
|                               | Xuefuzhuuyu Tang           | Taoren, Dansggu, Honghua, Chishao, Niuxi, Chuangxiong, Jiegeng, Chaihu, Zhiqiao, Shengdi-huang, Gancao     |
|                               | Zhenwu Tang                | Fuling, Shaoyao, Baizhu, Shengjiang, Fuzi               |
| Patent capsules or pills      | Danqi Pill                 | Danshen, Sanqi, Bingpian                                |
|                               | Fufang danshen Dripping Pill | Danshen, Sanqi, Bingpian                              |
|                               | Shengmai Capsule           | Renshen, Maidong, Wuwei                                |
|                               | Qili Qiangxin Capsule      | Huangqi, Renshen, Fuzi, Danshen, Tinglizi, Xieze, Yuzhu, Guizhi, Honghua, Xiangjiapi, Chenpi          |
|                               | Qishen Yiqi Dripping Pill  | Huangqi, Danshen, Sanqi, Jiangxiang                    |
| Patent injections             | Danhong Injection          | Danshen, Honghua                                       |
|                               | Huangqi Injection          | Huangqi                                                  |
|                               | Shenmai Injection          | Hongshan, Maidong                                       |
|                               | Shenuj Injection           | Hongshan, Fupian                                        |
|                               | Shengmai Injection         | Hongshan, Maidong, Wuwei                                |
Qili qiangxin capsule, another Chinese patent drug, was permitted for the treatment of HF by China Food and Drug administration (CFDA) in 2004. It contains extract of 11 Chinese herbs, including *Radix astragali*, Ginseng, *Radix aconiti carmichaeli*, *Salvia miltiorrhiza*, *Semen lepidii*, *Alismatis rhizoma*, etc. Among them, *Radix astragali* and *Radix aconiti carmichaeli* provide the fundamental active ingredients with pharmacological effect [30]. The efficacy of Qili qiangxin capsule was investigated in a double-blinded, multicenter, and randomized clinical trial, which enrolled 512 participants with systolic heart failure. The researchers reported that after 12 weeks of treatments, N-terminal prohormone of brain natriuretic peptide (NT-proBNP) level, which is considered as the most sensitive biomarker of HF, was down-regulated by Qili qiangxin capsule in 47.95% of patients. Furthermore, Qili qiangxin capsule demonstrated superior performance in comparison to the placebo in terms of NYHA functional classification, 6-min walking distance, LVEF and quality of life [31]. The promising results indicated that Qili qiangxin capsules could be prescribed with other medications for the treatment of chronic heart failure.

Huangqi injection, preparation of an extract of *Radix astragali*, is another commonly used Chinese patent medicine for clinical treatment of chronic heart failure. 62 randomized controlled trials (RCTs) and quasi-RCTs have been reviewed [23]. It was found that the methodologies of the trials were of low qualities and available studies were not robust enough to prove the efficacy and safety of Huangqi injection. Systematic reviews on the effects of hawthorn, cannabinoids and curcumin in treating chronic heart failure have also been conducted [32-34].

Di'ao Xinxuekang capsule was approved by CFDA and has been prescribed routinely in China for several years. Its components are mainly extracted from the rhizomes of *Dioscorea panthaica*. A randomized, multicenter, double-blinded trial was conducted to assess its effects on angina as compared with compound Danshan tablet [35]. Seven hundred and thirty three patients were included in the analysis set. After 20 weeks treatment, Xinxuekang capsule successfully reduced the proportion of angina pectoris patients. According to the results of measurement on the Seattle angina questionnaire score and blood stasis score, the qualities of life of patients were improved significantly by Xinxuekang. A review of randomized clinical trials on the efficacy of Xinxuekang capsule demonstrated that Xinxuekang capsule seemed to have a better effect on patients with angina pectoris as compared with isosorbide dinitrate [36].

Xinmailong is another patent Chinese medicine and the effective components are extracted from *Periplaneta Americana*. Xinmailong has been shown to have protective effects on ischemic myocardial injury [37, 38]. A systematic investigation with 121 patients in a course of 15 days explored the effects of Xinmailong on patients with heart failure, and compared its effects with the standard treatments [39]. In standard treatment group, patients received routine prescription including digitalis preparation, β-blockers, sodium nitroprusside as well as aspirin. Indicators of heart functions, including high sensitivity C-creative protein (hsCRP), NT_proBNP, LVEF and end systolic volume index of left ventricle, were restored towards normal levels by standard treatment and Xinmailong injections after 7 days of treatment. Xinmailong turned out to have a better performance after 15 days of treatment compared with standard treatment. LVEF was increased from 36.9% at the beginning of treatment to 46.4% after 15 days of treatment by Xinmailong (LVEF in normal group was 59.7%). This cardioprotective effect of Xinmailong might be achieved by its inhibition of angiotensin II, which in turn suppressed renin-angiotensin-aldosterone system [39].

Treating patients according to syndrome differentiation is an important aspect of TCM. In a multicenter, randomized control clinical trial with a total of 220 CHF patients, researchers reported that after 28 days, patients treated by Chinese herbs achieved better improvement of LVEF as compared with the placebo group. Patients in Chinese herbal medicine groups received different kinds of formulae according to syndrome differentiation. TCM syndrome scores also improved significantly in Chinese herbal medicine group compared to the placebo group. The only case of side effect was that one patient in Chinese herbal medicine group experienced atrial fibrillation [40]. The study showed that Chinese herbal medicine treatment according to syndrome differentiation effectively improved heart functions in patients with CHF and appeared to be safe. Another two studies with Nuanxin capsule and Shencao tongmai granule showed that after two weeks of treatment, the TCM syndrome scores of the CHF patients in the Chinese herbal medicine group decreased to levels lower than those observed in the placebo group. Chinese herbal medicine treatment can also markedly relieve the symptoms and signs of CHF patients [41, 42].

An issue facing clinical evaluations is that the concentrations of the effective components are usually unknown and the amounts of bioactive components may vary from one capsule to another [43]. The inconsistency of compounds in formulae or capsules warrants that the results of clinical trials should be received with cautious optimism. Despite the challenges, the clinical trials will open opportunity to explore how the multi-components in TCM exert integrated effect on the syndrome of heart failure [44].

4. THE MECHANISMS OF TCM IN TREATING HF

The pharmacological mechanisms of TCM in treating heart failure have been explored in numerous studies. The most commonly used animal model in these studies is acute myocardial ischemia (AMI) model or doxorubicin (DOX)-induced cardiac toxic model. In vitro studies on H9C2 cardiac cell lines have also been extensively conducted. The investigated forms of TCM include single herb, extracts of herbs and formulae. The experimental studies demonstrate that TCM possess properties of anti-fibrosis, anti-inflammation, anti-oxidant, anti-apoptosis, pro-angiogenesis and metabolism regulation (Table 2). These biological pathways are interconnected with each other and TCM may function in a multi-components and multi-targets mode.

4.1. TCM that Exert Anti-Fibrotic Effects

Fibrosis results from a number of cardiovascular diseases. The accumulation of fibroblasts and deposition of extracellular matrix often lead to the distortion of organ architecture and cardiac dysfunction. Transforming growth factor β1 (TGF-β1) acts as one of critical regulatory factors involved in the progression of fibrosis [45]. Progress has been made in the anti-fibrotic treatments by targeting TGF-β1 [46]. Collagen I (Col I), collagen III (Col III), matrix metalloproteinase-2 (MMP-2) and MMP-9 are the most commonly detected molecules, as they are the main contributors to extracellular matrix remodeling [47, 48]. Several herbs have been shown to have anti-fibrotic effects.

Xuefuzhuyu decoction, a TCM used for coronary heart disease, is composed of 11 compounds. A study showed that Xuefuzhuyu decoction treatment could decrease cardiac fibrosis induced by hypertension and inhibit expression of TGF-β1 [49]. The bioactive components of Xuefuzhuyu that attenuate myocardial fibrosis by acting on TGF-β1 signaling pathways may include carthamin yellow, ferulic acid sodium, ligustrazine, amygdalin and paeoniflorin which are extracted from *Carthamus tinctoria*, *Angelica sinensis*, *Ligusticum striatu*, *Prunus persica* and *Paeonia lactiflora Pall*, respectively.

Shengmai yin, used for treating coronary heart disease with “qi-yin” deficiency, is composed of *Radix ginseng*, *Radix ophiopogonis* and *Fructus schisandrae* at the ratio of 1:2:1. Shengmai yin showed protective effect against cardiac toxicity induced by DOX in rats. Rats treated with Shengmai yin showed reduction of monocyte chemotactant protein-1 (MCP-1) and B-type natriuretic peptide. Myocardial fibrosis was suppressed by Shengmai yin, as evidenced
by suppression of amino terminal propeptide of procollagen type III, carboxyl terminal propeptide of procollagen type I (PICP) and TGF-β1 [50]. Shensongyangxin capsule has long been used clinically to treat arrhythmias. Experiments in a rabbit model demonstrated that Shensongyangxin capsule could decrease the protein levels of Col I and Col III, TGF-β1, MMP2, thereby ameliorating electrophysiological dysregulations in ischemic hearts [51]. It was also demonstrated that Shensongyangxin capsule inhibited fibrosis in streptozocin-induced diabetic rats with high fat-diet and improved cardiac function via TGF-β1/Smad signaling pathway [52].

Sini tang is composed of four herbs: Aconitum carmichaelii, Cinnamomum cassia, Zingiber officinale, and Glycyrrhiza uralensis. The concentrations of Toll-like receptors (TLR-2 and TLR-4) in cardiac tissue could be down-regulated significantly by Sini tang. Meanwhile, the levels of collagens in plasma and in cardiac tissue were also reduced. The similar results were got in terms of the plasma and cardiac levels of TGF-β1, suggesting that Sini tang could prevent against early ventricular hypertrophy and improve post-AMI cardiac function [53]. Nanmu xiang, also known as aristolochia yunnanensis, has been proven to be effective in the treatment of hypertension and chest pain. It was shown that extract of

| Property                        | Herbs or Extracts | Target or Indicator | Type of Study | References |
|---------------------------------|-------------------|---------------------|---------------|------------|
| Anti-fibrosis                   | Xuefuzhu decoction| TGF-β1              | in vivo       | [49]       |
|                                 | Shengmai yin      | BNP, MCP-1, PICP proCol III, TGF-β1 | in vivo | [50]       |
|                                 | Shensong yangxin  | col I and col III, TGF-β1, MMP2 | in vivo | [51, 52]  |
|                                 | Sini tang         | TLR-2, TLR-4, TGF-β1 | in vivo | [53]       |
|                                 | Nanmu xiang       | ERK1/2, TGF-β1, Smad 2 | in vivo, in vitro | [54] |
|                                 | Qishenyiqi dripping pill | MMP-2, MMP-9, col I, col III, IL6, STAT3, TNFα, NF-κB, TGF-β1 | in vivo, in vitro | [55-59] |
|                                 | Zhenwu tang       | collagen             | in vivo       | [60]       |
| Anti-inflammation               | Qishenyiqi dripping pill | PLA2, COX1, COX2, AT1, AT2, NF-κB, JAK1, STAT3, Akt | in vivo | [55]       |
|                                 | PNS               | LXRα, ABCA1, NF-κB   | in vivo, in vitro | [70] |
|                                 | Danqi pill        | leukotrienes B4, COX1, COX2, PLA2, NF-κB, thromboxane B2, prostaglandin I2 | in vivo | [71, 72]  |
| Pro-angiogenesis                | Shumai tang       | Akt, VEGF, PDGF, PI3K | in vivo | [76]       |
|                                 | Ginsenoside       | PI3K, Akt            | in vivo       | [77]       |
|                                 | Danqgsui          | VEGF                 | in vivo, in vitro | [78] |
|                                 | Qishenyiqi dripping pill | HIF-1α, VEGF, MAPK, PI3K and AKT | in vivo | [80-83] |
| Anti-oxidation                  | Danshen           | ROS, LDL, ERK1/2, JNK, NAD(P)H oxidase, Bcl-2, Bax, caspase-3 | in vivo, in vitro | [91-99] |
|                                 | Zhuzi shen        | MDA, NO, CK, NOS     | in vivo       | [100]      |
|                                 | Manshan hong      | GSH-Px, SOD, MDA, ROS | in vitro | [101]      |
|                                 | Ginkgo biloba     | ROS, VACM-1          | in vitro     | [102]      |
| Anti-apoptosis                  | Qiliqiangxin capsule | ROS, Fas, caspase-3 | in vivo | [108]      |
|                                 | Buyinhuangwu decoction | Bcl-2, Bax, caspase-3 | in vivo | [109]      |
|                                 | Dioscin           | Bcl-2, Bax, ROS, MDA, cytochrome c | in vitro | [110, 111] |
|                                 | PNS               | p-AKT, PI3K          | in vivo, in vitro | [112] |
|                                 | Shengmai injection | caspase-12           | in vivo       | [113]      |
|                                 | Protocatechuic aldehyde | caspase-3            | in vitro | [114]      |
|                                 | Tanshinone IIA    | P38 MAPK, mir-1      | in vivo       | [118]      |
| Regulating energy metabolism    | Danqi pill        | ApoA-1, CD36, FABP, CPT-1A, LPL | in vivo | [72, 122]  |
|                                 | Qishenyiqi dripping pill | ATP, PPARα, PGC-1α, SOD, MDA, TNFα, IL-1α | in vivo | [123-125] |
|                                 | Shengmai decoction | amino acids, arachidonic acid, etc. | in vivo | [126]      |

Sini tang is composed of four herbs: Aconitum carmichaelii, Cinnamomum cassia, Zingiber officinale, and Glycyrrhiza uralensis. The concentrations of Toll-like receptors (TLR-2 and TLR-4) in cardiac tissue could be down-regulated significantly by Sini tang. Meanwhile, the levels of collagens in plasma and in cardiac tissue were also reduced. The similar results were got in terms of the plasma and cardiac levels of TGF-β1, suggesting that Sini tang could prevent against early ventricular hypertrophy and improve post-AMI cardiac function [53]. Nanmu xiang, also known as aristolochia yunnanensis, has been proven to be effective in the treatment of hypertension and chest pain. It was shown that extract of
Aristolochia yunnanensis could inhibit angiotensin II induced cardiac fibrosis through extracellular signal regulated kinase 1/2 (ERK1/2) and TGF-β1/Smad pathways [54].

QSYQ is prescribed frequently for treating cardiovascular diseases including heart failure. Current research demonstrated that QSYQ exerted anti-fibrotic effect in AMI rat models by inhibiting renin-angiotensin-aldosterone system (RAAS), including blocking the type I receptor of angiotensin II (AT1), activating type II receptor of angiotensin II (AT2), down-regulating angiotensin-converting enzyme (ACE), and up-regulating ACE 2. Both Cyclooxygenase 1 (COX1) and COX2 in arachidonic acid (AA) pathway activated by RAAS were also inhibited. Myocardial fibrosis biomarkers, including matrix metalloproteinase-2 (MMP-2), MMP-9, collagen I and collagen III, were regulated by QSYQ treatment. In addition, “therapeutic” QSYQ administration could suppress the release of pre-inflammatory factors including tumor necrosis factor α (TNFα) and interleukin 6 (IL-6) [55, 56]. Other studies also confirmed that QSYQ had definite effect on myocardial fibrosis and slowed down the progression of cardiac hypertrophy [57, 58]. Danshen is a composite of QSYQ and study showed that Danshen alone prevented myocardial fibrosis which was induced by chronic iron overload in mice. Further study demonstrated that Danshen treatments was capable of increasing expressions of TGF-β1 and MMP-9, reducing level of iron deposition, fibrotic area and contents of collagen I and collagen III in a dose-dependent manner [59]. Zhenwu tang was shown to inhibit collagen hyperplasia and fibrosis in a myocardial hypertrophy rat model [60].

4.2. TCM that Attenuate Inflammation

Inflammation has been proven to be the major pathological changes in heart failure [61, 62]. An intense inflammatory response can be initiated by ischemic injury in heart tissue, which usually leads to further cardiac dysfunction [63]. Several signaling pathways, including phospholipase A2 (PLA2)/cyclooxygenases (COXs) and IL-6-janus kinase (JAK)/STAT3, are involved in the inflammatory process [64]. Inflammatory responses can eventually lead to fibrosis and ventricular remodeling [65]. Therefore, the effects of TCM on inflammation and fibrosis are inter-connected with each other. Our studies showed that QSYQ could attenuate myocardial fibrosis in AMI model rats by reducing expression of AT1 and increasing expression of AT2 in RAAS pathway. The inflammatory signaling pathway was also attenuated by QSYQ. In particular, the QSYQ had a similar effect with aspirin which could unselectively inhibit both the expressions of COX1 and COX2. Furthermore, QSYQ suppressed levels of NF-kB, JAK1, STAT3 and Akt, the contributing factors to myocardial inflammation and fibrosis [55]. Several specific Chinese herbs, such as Capsitis chinensis (huanglian), Scutellaria baicalensis (huangqi), Flos Lonicerae (jinyin-hua) and Forsythia suspensa (lianqiao), have also been shown to have anti-inflammatory properties [66, 67].

DQP, prepared from equal amounts of Salvia miltiorrhiza and Panax notoginseng, is frequently prescribed for the treatment of coronary heart disease. The major active ingredients in DQP are salvianolic acids and panax notoginseng saponins (PNS) [68, 69]. PNS could attenuate atherosclerosis by inducing expression of liver X receptor α (LXRA), and inhibiting NF-kB DNA binding activity [70]. Our study showed that DQP regulated multiple biological processes, including AA metabolism, in AMI rat model [71]. It down-regulated expression of thrombocyte B2 and up-regulated expression of prostaglandin I2. DQP also suppressed productions of COX1, COX2 and leukotrienes B4. Expressions of PLA2 in AA pathways are suppressed by DQP treatment [72].

4.3. TCM that Regulate Angiogenesis

An insufficient supply of blood to the cardiac tissues is characteristic of ischemic heart disease [73]. Therefore, a therapeutic strategy to treat ischemic heart failure is to restore blood supply by stimulating the growth of new blood vessels [74]. Studies have shown that various angiogenic growth factors and progenitor cells, including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), recombiant proteins and bone marrow stem cells, can enhance new blood vessels and stimulate angiogenesis [75]. Some components of Chinese herbs have been shown to be able to promote development of new blood vessels. Shumai tang, a TCM for ischemic heart disease treatment, consists of seven medicinal components. The major effective ingredients of Shumai tang include astragaloside, salvianolic acid, scanthinose, ginsenoside Rg1, etc. A study showed that Shumai tang significantly increased densities of capillaries and arterioles, attenuated myocardial fibrosis, and up-regulated cardiac phosphorylation of protein kinase B (Akt), increased expressions of VEGF and platelet-derived growth factor (PDGF-BB). These effects may be exerted by activation of the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway in AMI rat model [76]. Ginsenoside-Rg1 could also promote angiogenesis and attenuate myocardial fibrosis by activating PI3K/Akt and inhibiting P38 mitogen-activated protein kinases (p38 MAPK) [77]. Study demonstrated that Angelica and Chaumxiang, which are used as treatment for ischemic heart disease, could increase expressions of VEGF in the ischemic heart tissues of rats, stimulate proliferation of endothelial cells and increase densities of vessels on chick embryo chorioallantoic membrane model [78].

MicroRNAs (miRNA) play a key role in regulating gene expression, mainly through blocking translation of target mRNA or inducing degradation of mRNA [79]. miRNAs also play important roles in angiogenesis and cardiovascular diseases. A study found that QSYQ promoted angiogenesis by targeting miR-223p, one of the key miRNAs in regulating angiogenesis of microvascular endothelial cells without blood supply. Expressions of HIF-1α, VEGF, MAPK, PI3K and AKT in hypoxia-inducible factor 1α (HIF-1α) signaling pathway were increased remarkably by QSYQ [80]. Other studies showed that the components of QSYQ promoted angiogenesis through activating PI3K/Akt pathway and up-regulating expressions of HIF-1α and VEGF [81-83]. It is worthy of noting that some herbs are antiangiogenic and have been applied for the treatment of cancers and decompensated heart failure [84].

4.4. TCM with Anti-Oxidative Property

Oxidative stress is caused by excessive production of reactive oxygen species (ROS) and it’s an important contributor to cardiac remodeling and heart failure. ROS can be produced by several intracellular enzymes, including NAD(P)H oxidase, xanthine oxidase, and uncoupled nitric oxide synthase. Increased ROS level leads to mitochondrial damage, up-regulation of MMPs and cardiac hypertrophy [85]. The plasma level of malondialdehyde (MDA) produced by lipid peroxidation rose in heart failure patients. NAD(P)H levels of oxidase-derived ROS and plasma TNFa were also increased [86, 87]. Oxidative stress is also one of the most potent inducers of endothelial dysfunction and is involved in atherosclerotic plaque evolution [88-90]. Antioxidants have the potential to protect against the harmful effects of oxidative stress and many natural plant products have such properties of antioxidants. Trilinolein is extracted from Panax notoginseng and has been found to have antioxidant activity [91]. Shankha and Danshen are used together to treat cardiovascular diseases. Both Shankha and Danshen exhibited high antioxidant activities [92-94]. The active components of Shankha are mainly phenolic compounds, whereas the active components of Danshen have been identified as salvianolic acid A and B [95]. Phenolic compounds not only exerted antioxidant activities, but also inhibited formation of oxidized low density lipoprotein (ox-LDL) [96]. Salvianolic acid B was the major effective component of the Shankha and danshen capsule and exhibited strong antioxidant activity compared with other phenolic compound [97]. Treatment with salvianolic acid B reduced phosphorylation of ERK1/2 and JNK and suppressed production of prostaglandin E2 (PGE2) and NAD(P)H oxidase activity in human aortic smooth muscle cells.
treated with LPS, indicating that salvianolic acid B had antioxidant properties [98]. Tanshinone IIA, another main component of Dan-shen, could significantly inhibit the production of H2O2-induced ROS. Tanshinone IIA was able to significantly decrease the expression of Bax and caspase-3 evoked by H2O2 in vitro and increase the level of anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) in EA.hy926 cells [99]. A study showed that polysaccharides of Zhuzishen (Rhizoma panaxis majoris) could alleviate oxidative stress response, reduce levels of its products, MDA and nitric oxide (NO), and inhibit activities of creatine kinase (CK) and nitric oxide synthase (NOS) in a rat model of congestive heart failure [100]. Furthermore, an extract from the Chinese herb Manshan hong (Rhododenron dauricum), could significantly inhibit the H2O2-induced loss of cell viability and enhance activities of protective enzymes in oxidative stress pathway including superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in EA.hy926 cells. In addition, farrerol inhibited the H2O2-induced elevation of intracellular MDA and ROS [101]. Extract from Ginkgo biloba could attenuate intracellular ROS formation, redox-sensitive transcription factor activation, and expressions of vascular cell adhesion molecule 1 (VCAM-1) as well as intercellular adhesion molecule 1 in human aortic endothelial cells, thereby suppressing endothelial adhesion induced by inflammatory cytokine to human mononcytic cells [102]. Herbs with anti-oxidative properties were summarized by a previous review [14].

4.5. TCM that Suppress Apoptosis

Apoptosis contributes to the progression of a variety of cardiovascular diseases and inhibition of myocardial apoptosis is a potential strategy for the treatment of cardiovascular diseases. Caspases have been considered as the major promising targets, as their induction and execution are essential to evaluate the activation and inhibition of apoptosis. Caspases are used as the common biomarkers for different apoptotic pathways [103]. In addition, Bcl-2 family members, including both pro-apoptotic and anti-apoptotic proteins, play complicated roles in myocardial ischemia/reperfusion (I/R) [104-107]. Some Chinese medicines exert cardio-protective effects by inhibiting apoptosis in myocardium. Qiangxian capsule was shown to inhibit cardiomycocyte apoptosis in ischemic heart tissues. The potential mechanism may be involved with its ability to reduce ROS and to depress the expression of Fas and caspase-3 [108]. Buyinghuangwan decoction could attenuate ligation of Left Anterior Descending Artery (LAD) -induced ventricular remodeling, by up-regulating Bcl-2/Bax ratio and down-regulating caspase-3 activity [109]. Dioscin is an extracted saponin from the roots of Huai-shan-Dao (Dioscorea nipponica Makino) [110]. Dioscin alleviated cell death and reduced level of lactate dehydrogenase (LDH) in I/R-stimulated H9C2 cells. Dioscin also attenuated cellular apoptosis through regulating expressions of Bax and Bcl-2. Cytochrome c release, intracellular ROS and MDA levels were also reduced by dioscin [111]. PNS were shown to exhibit anti-apoptotic effect both in vitro and in vivo. This effect was probably mediated by activating PI3K/Akt pathway, as the anti-apoptotic effect was neutralized by PI3K inhibitor LY294002 [112]. Shenmai injection could alleviate endoplasmic reticulum stress and inhibit caspase-12 dependent apoptosis, thereby protecting against DOX-induced heart dysfunction [113]. Protocatechuic aldehyde, derived from Danshen, is water-soluble antioxidant. Research found that protocatechuic aldehyde could inhibit apoptosis induced by lipopolysaccharide in human umbilical vein endothelial cells through regulating caspase-3 expression in a dose-dependent manner [114].

Some microRNAs, such as cardiac muscle specific Mir-1, play critical roles in growth of muscle, and therefore it can directly affect the cardiac function [115]. Meanwhile, the activation of phosphorlation of p38 MAPK could result in myocardial damage and apoptosis [116, 117]. Tanshinone IIA was shown to have protective effects against ischemic or hypoxic induced cardiac injury. This effect was achieved by regulating expression of mir-1 and suppressing activation of p38 MAPK signaling pathway [118].

4.6. TCM that Regulate Mitochondrial Functions and Energy Metabolism in HF

Pumping blood to meet the need of body relies heavily on the supply of adenosine triphosphate (ATP). Oxidation of nutrients, including fatty acids, glucose, lactate, ketone bodies and amino acids, is the source of ATP. Fatty acids provide 70% to 90% of cardiac ATP. Glucose, lactate and a small amount of amino acids provide the left 10% to 30% of ATP needed by the heart [119]. Since the lipid metabolism dominates the energy supply for the heart, lots of studies focused on regulation of it for the treatment of heart disease. Among them, peroxisome proliferator activated receptors α (PPARα) was intensively investigated as it participated in the whole process of lipid metabolism. The level of very low density lipoprotein (VLDL) in plasma could be reduced by activation of PPARα which inhibits the formation of both triglyceride and cholesterol [120, 121]. Therefore, activating PPARα by agonists is a potential strategy for the treatment of CHD. Herbal medicine could regulate cardiac metabolism and exert cardio-protective effects in the treatment of heart failure. Previous study showed that DQP up-regulated PPARα expression significantly in AMI model [72]. Our research also demonstrated that DQP could intervene the transportation, absorption, distribution as well as metabolism of fatty acids in AMI model rats by regulating expressions of essential proteins, including apolipoprotein A-1 (ApoA-I), cluster of differentiation 36 (CD36), fatty acid binding protein (FABP), carnitine palmitoyl transferase I (CPT-1A) and lipoprotein lipase (LPL) in the heart tissues. Conclusively, DQP had a comprehensive regulatory effect on lipid metabolic process in AMI rats [72, 122].

Another TCM study on lipid metabolism showed that QSYQ treatment could attenuate DOX-induced cardiac injury and protect against damage of cardiac structure. DOX caused damage to heart function by reducing protein content of ATP 5D, PPARα, as well as peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α) [123]. Meantime, a parallel study found that ATP levels and mitochondrial transmembrane potential (MTP) in AMI heart were restored by QSYQ pretreatment for 7 days. Pretreatment with QSYQ also regulated plasma SOD, MDA, TNFα and IL-1β. QSYQ improved energy metabolism and reduced oxidative stress by attenuating I/R-induced mitochondrial abnormalities [124]. The effects of QSYQ on energy metabolism were also investigated by proteomic study. The results demonstrated that QSYQ treatment regulated expressions of proteins involved in oxidative stress and energy metabolism. Due to interactions of its bioactive ingredients, QSYQ had a better anti-hypertrophic effect than its single ingredients or combinations of several ingredients. Among those ingredients of QSYQ, 3,4-dihydroxy-phenyl lactic acid was the best candidate for countering oxidative stress. Astragaloside IV and nobiletin were more potent at regulating energy metabolism [125]. Another well-known prescription, Shenfu decoction, was found to exert therapeutic efficacies in rats with chronic HF. Results of urinary and plasma metabolomics suggested that inflammation and dysfunctions of energy metabolisms were associated with 16 potential urine biomarkers and 13 potential plasma biomarkers. Shenfu decoction could partly restore the disturbed pathways that the differentially expressed biomarkers were enriched on [126].

CONCLUSION

Heart failure is related with multiple risk factors. Therefore, multi-target treatments may be more effective in treating HF. The combined application of herbal and chemical drugs is becoming a new trend of modern medicine in preventing and treating diseases nowadays. The promise of Chinese herb-derived compounds as effective therapeutics for heart failure has been indicated by clinical
evaluations and experimental studies [127]. Chinese herbs have been shown to have anti-fibrosis, anti-inflammation, anti-oxidation, anti-apoptosis, pro-angiogenesis and metabolism regulatory effects. However, the published studies have several limitations. Firstly, most of the clinical studies contain a small sample size or incomplete data. The exclusion and inclusion criteria are not specific or not even mentioned in some of the studies. There is a lack of double-blinded, multi-center, randomized and controlled clinical trial for most of the compounds used in treating HF. Secondly, other than patent drugs, most of the formulae prescribed by doctors contain varied amounts of components and the treatment period also vary from person to person. Therefore, it is difficult to make accurate evaluations of the efficacies of the herbs in TCMP practice in a systematic way. Thirdly, it is believed that combination of herbs could attenuate toxicity as well as enhance efficacy. Toxic side effects could occur by treatment with some herbs. However, published in vivo studies seldom mention the adverse effects of the treatments. The systemic and organ-specific toxic effects and the minimally toxic dose for most of herbs are still to be investigated by animal studies and clinical studies. Fourthly, in modern medical practice, it is more likely that Chinese herbs are used together with other drugs to treat cardiovascular diseases and heart failure. Therefore, herb-drug interaction should be taken into consideration and should be carefully evaluated in future studies. Moreover, the active ingredients in different compounds are still not clear and their targets are still inconclusive. The development of systems biology and network pharmacology provides us with tools to analyze and predict large-scale drug-target interactions [20, 128-132]. Finally, heart failure is a multiple-stage condition caused by multiple factors. Most of the published investigations are focused on examining the effects of Chinese medicine on one or a few aspects of heart failure. A systematic evaluation of the mechanisms of TCM should be performed. In spite of all these challenges, further well designed clinical trials and experimental studies will facilitate better understanding of the mechanism of TCM and promote the modernization of TCM in the treatment and prevention of heart failure.

LIST OF ABBREVIATIONS

| Abbreviation | Meaning |
|--------------|---------|
| AA           | Arachidonic Acid |
| ABCA1        | ATP-binding Cassette A1 |
| Akt          | Protein Kinase B |
| AMI          | Acute Myocardial Ischemia |
| ApoA-I       | Apolipoprotein A-I |
| AT1          | Angiotensin Type 1 Receptor |
| ATP          | Adenosine Triphosphate |
| Bcl-2        | B-cell Lymphoma 2 |
| BNP          | Brain Natriuretic Peptide |
| CD36         | Cluster of Differentiation 36 |
| CHD          | Coronary Heart Diseases |
| CK           | Creatine Kinase |
| Col          | Collagen |
| COX          | Cyclooxygenase |
| CPT-1A       | Carnitine Palmitoyl Transferase I |
| DOX          | Doxorubicin |
| DQP          | Danqi Pill |
| ERK          | Extracellular Signal Regulated Kinase |
| FABP         | Fatty Acid Binding Protein |
| FGF          | Fibroblast Growth Factor |
| GSH-Px       | Glutathione Peroxidase |
| HF           | Heart Failure |
| HIF-1α       | Hypoxia-inducible Factor 1α |
| I/R          | Ischemia/reperfusion |
| IL-6         | Interleukin 6 |
| JAK          | Janus Kinase |
| LPL          | Lipoproteinlipase |
| LVEF         | Left Ventricular Ejection Fraction |
| LXRα         | Liver X Receptor α |
| MCP-1        | Monocyte Chemoattractant Protein-1 |
| MDA          | Malondialdehyde |
| miRNA        | microRNA |
| MMP          | Matrix Metalloproteinase |
| NF-κB        | Nuclear Factor-κB |
| NOS          | Nitric Oxide Synthase |
| NT-proBNP    | N-terminal Prohormone of Brain Natriuretic Peptide |
| NYHA         | New York Heart Association |
| p38 MAPK     | P38 Mitogen-activated Protein Kinas |
| PDGF-BB      | Platelet-derived Growth Factor |
| PGC-1α       | Peroxisome Proliferator-activated Receptor Gamma Coactivator 1α |
| PI3K         | Phosphoinositide 3-kinase |
| PICP         | Carboxyl Terminal Peptide of Procollagen Type 1 |
| PLA2         | Phospholipase A2 |
| PNS          | Panax Notoginseng Saponins |
| PPARα        | Peroxisome Proliferator Activated Receptors α |
| QSYQ         | Qishenyiqi Dripping Pill |
| RAAS         | Renin-angiotensin-aldosterone System |
| ROS          | Reactive Oxygen Species |
| SOD          | Superoxide Dismutase |
| STAT3        | Signal Transducer and Activator of Transcription 3 |
| TCM          | Traditional Chinese Medicine |
| TGF-β1       | Transforming Growth Factor β1 |
| TLR          | Toll-like Receptors |
| TNFα         | Tumor Necrosis Factor |
| VCAM-1       | Vascular Cell Adhesion Molecule 1 |
| VEGF         | Vascular Endothelial Growth Factor |
| VLDL         | Very Low Density Lipoprotein |

CONSENT FOR PUBLICATION

Not applicable.

CONFLICT OF INTEREST

The authors declare no conflict of interest. Preparation of this manuscript was supported by grants from the National Natural Science Foundation of China (No. 81673712, 81470191, 81302908, 81503379 and 81530100), Fok Ying Tung Education Foundation (No. 151044), Beijing Nova program (Z1711000117028), Beijing Natural Science Foundation (No.7142099) and excellent young scientist foundation of BUCM (2015-JYB-XYQ001, 2015-JYB-QNJSZX001 and No.2016-JYB-XJ003).
ACKNOWLEDGEMENTS
We thank Dr. Xia Kai and Zeng Zifan for their advice on earlier versions of this manuscript.

REFERENCES
[1] Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005; 111: 2837-49.
[2] Lehnhart SE. Understanding the physiology of heart failure through cellular and in vivo models-towards targeting of complex mechanisms. Exp Physiol 2013; 98: 622-8.
[3] Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933-89.
[4] Al-Mohammad A, Mant J. The diagnosis and management of chronic heart failure: review following the publication of the NICE guidelines. Heart 2011; 97: 411-6.
[5] Guidelines for the diagnosis and management of chronic heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 2007; 35: 1076-95.
[6] Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2016.
[7] Gupta A, Ghimire G, Hage FG. Guidelines in review: 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Nucl Cardiol 2014; 21: 397-9.
[8] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-239.
[9] Zhao QZ, Mao JY, Wang XL, et al. Application and evaluation of Chinese medicine in treatment of chronic heart failure. Zhongguo Zhong Xi Yi Jie He Za Zhi 2013; 33: 1701-4.
[10] Chen C, Meng YM, Zhang P, et al. Diagnosis and treatment rule of traditional Chinese medicine for syndrome factors of chronic congestive heart failure: a study based on Shannon entropy method. Zhong Xi Yi Jie He Xue Bao 2010; 8: 1080-4.
[11] Zhou JX, Tang M, Li J. Analysis of Chinese syndrome features and combination laws of 2029 patients with coronary heart disease angina. Zhongguo Zhong Xi Yi Jie He Za Zhi 2011; 31: 753-5.
[12] Liang D, Zhang M. The thinking on TCM differential treatment of congestive heart failure. J Tradit Chin Med 2000; 20: 44-7.
[13] Kong QF, Song SX, Xie XY. Clinical study on therapeutic effects of treatment according to syndrome differentiation of traditional Chinese medicine combined with catapril on severe viral myocarditis complicated heart failure. Zhongguo Zhong Xi Yi Jie He Za Zhi 2001; 21: 513-5.
[14] Shang H, Zhang J, Yao C, et al. Qi-shen-yi-qí dripping pills for the secondary prevention of myocardial infarction: a randomised clinical trial. Evid Based Complement Alternat Med 2013; 2013: 738391.
[15] Liu YZ, Wang S, Zhao ZQ, et al. Clinical assessment of complementary treatment with Qishen Yiqi dripping pills on ischemic heart failure: study protocol for a randomized, double-blind, multicenter, placebo-controlled trial (CACT-IFH). Trials 2013; 14: 138.
[16] Liu Y, Ouyang Y, Li S, et al. Determination of twelve active compounds in Qili Qiangxin capsules by UPLC-MS. Zhongguo Zhong Xia Yao Za Zhi 2015; 39: 1822-5.
[17] Li X, Zhang J, Huang J, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of gili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol 2013; 62: 1065-72.
[18] Durst R, Lotan C. The potential for clinical use of cannabinoids in treatment of cardiovascular diseases. Cardiovasc Ther 2011; 29: 17-22.
[19] Pittler MH, Guo R, Ernst E. Hawthorn extract for treating chronic heart failure. Cochrane Database Syst Rev 2008: CD005312.
[20] Wongsurawat P, Phrommintikul A. The protective role of curcumin in cardiovascular diseases. Int J Cardiol 2009; 133: 145-51.
[21] Tian R, Chen L, Yang Y, et al. Study on traditional Chinese medicine prescriptions for cardiovascular diseases over the past 20 years and logistic regression analysis. Zhongguo Zhong Yao Za Zhi 2012; 37: 541-4.
[22] Ceylan-Isik AF, Fleetham RM, Wold LE, et al. Herbal and traditional Chinese medicine for the treatment of cardiovascular complications in diabetes mellitus. Curr Diabetes Rev 2008; 4: 320-8.
[23] Fu S, Zhang J, Menniti-Ippolito F, et al. Huangqi injection (a traditional Chinese patent medicine) for chronic heart failure: a systematic review. PLoS One 2011; 6: e19604.
[24] Chen CX, Gao JB, Wu Q, et al. Progress in treatment of chronic heart failure in Western medicine and treatment strategies in traditional Chinese medicine. Zhong Xi Yi Jie He Xue Bao 2010; 8: 7-14.
[25] Chen J, Wu G, Li S, et al. Shengmai (a traditional Chinese herbal medicine) for heart failure. Cochrane Database Syst Rev 2007: CD005952.
[26] Jian M. Clinical observation of congestive heart failure treated by integrated traditional Chinese and Western medicine. Zhongguo Zhong Xi Yi Jie He Za Zhi 2002; 22: 542, 4.
[27] Kong QF, Song SX, Xie XY. Clinical study on therapeutic effects of treatment according to syndrome differentiation of traditional Chinese medicine combined with captopril on severe viral myocarditis complicated heart failure. Zhongguo Zhong Xi Yi Jie He Za Zhi 2001; 21: 513-5.
[28] Shang H, Zhang J, Yao C, et al. Qi-shen-yi-qí dripping pills for the secondary prevention of myocardial infarction: a randomised clinical trial. Evid Based Complement Alternat Med 2013; 2013: 738391.
[29] Liu YZ, Wang S, Zhao ZQ, et al. Clinical assessment of complementary treatment with Qishen Yiqi dripping pills on ischemic heart failure: study protocol for a randomized, double-blind, multicenter, placebo-controlled trial (CACT-IFH). Trials 2013; 14: 138.
[30] Liu Y, Ouyang Y, Li S, et al. Determination of twelve active compounds in Qili Qiangxin capsules by UPLC-MS. Zhongguo Zhong Xia Yao Za Zhi 2015; 39: 1822-5.
[31] Li X, Zhang J, Huang J, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of gili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol 2013; 62: 1065-72.
randomized, parallel controlled trial. Zhongguo Zhong Xi Yi Jie He Za Zhi 2012; 32: 612-5.

[43] Li X, Chen H, Jia W, et al. A metabolomics-based strategy for the quality control of traditional chinese medicine: shengmai injection as a case study. Evid Based Complement Alternat Med 2013; 2013: 836179.

[44] Tang WH, Huang Y. Cardiotoxic modulation in heart failure: insights from traditional Chinese medicine. J Am Coll Cardiol 2013; 62: 1073-4.

[45] Leask A. TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res 2007; 74: 207-12.

[46] Yoshimatsu Y, Watabe T. Roles of TGF-beta signals in endothelial-mesenchymal transition during cardiac fibrosis. Int J Inflamm 2011; 2011: 724080.

[47] Lopez B, Gonzalez A, Varo N, et al. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001; 38: 1222-6.

[48] Fan D, Takawale A, Lee J, et al. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair 2012; 5: 15.

[49] Zhang G, Yang G, Deng Y, et al. Ameliorative effects of Xue-Fu-Zhu-Yu decotion, Tian-Ma-Gou-Teng-Yin and Wen-Dan decotion on myocardial fibrosis in a hypertensive rat mode. BMC Complement Altern Med 2016; 16: 56.

[50] Mu L, Li X, Dong L, et al. Protective effect of Sheng-Mai Yin, a traditional Chinese preparation, against doxorubicin-induced cardiac toxicity in rats. BMC Complement Altern Med 2016; 16: 61.

[51] Dang S, Huang CX, Wang X, et al. Shensong Yangxing (SSXY) ameliorates disordered excitation transmission by suppressing cardiac collagen hyperplasia in rabbits with chronic myocardial infarction. J Huazhong Univ Sci Technolog Med Sci 2016; 36: 162-7.

[52] Shen N, Li X, Zhou T, et al. Shensong Yangxing Capsule prevents diabetic myocardial fibrosis by inhibiting TGF-beta1/Smad signalling. J Ethnopharmacol 2014; 157: 161-70.

[53] Liu J, Peter K, Shi D, et al. Traditional formula, modern application: chinese medicine formula sini tang improves early ventricular remodeling and cardiac function after myocardial infarction in rats. Evid Based Complement Alternat Med 2014; 2014: 141938.

[54] Shao W, Li D, Peng J, et al. Inhibitory effect of ethyl acetate extract of Aristolochia yunnanensis on cardiac fibrosis through extracellular signal-regulated kinases 1/2 and transforming growth factor beta/smaller mother against decapentaplegic signaling pathways. Transl Res 2014; 163: 160-70.

[55] Wang J, Lu L, Wang Y, et al. QiShenYiQing Dropping Pill attenuates myocardial fibrosis in rats by inhibiting RAAS-mediated arachidonic acid inflammation. J Ethnopharmacol 2015; 176: 375-84.

[56] Li C, Wang Y, Qiu Q, et al. QiShenYiQing protects ligation-induced left ventricular remodeling by attenuating inflammation and fibrosis via STAT3 and NF-kappaB signaling pathway. PLoS One 2014; 9: e104255.

[57] Li YC, Liu YY, Hu BH, et al. Attenuating effect of post-treatment with QShen YiQI Pills on myocardial fibrosis in rat cardiac hypertrophy. Clin Hemorheol Micropulse 2012; 51: 177-91.

[58] Zhang L, Wang Y, Yu L, et al. QI-SHEN-YI-QI accelerates angiogenesis after myocardial infarction in rats. Int J Cardiol 2010; 143: 105-9.

[59] Zhang Y, Wang H, Cui L, et al. Continuing treatment with Salvia miltiorrhiza injection attenuates myocardial fibrosis in chronic iron-overloaded mice. PLoS One 2015; 10: e0124061.

[60] Xie ZX, Wang SY, Liang ZJ, et al. Effect of Zhenwu Tang Granule on pressure-overloaded left ventricular myocardial hypertrophy in rats. World J Emerg Med 2010; 1: 149-53.

[61] Marchant DJ, Boyd JH, Lin DC, et al. Inflammation in myocardial diseases. Circ Res 2012; 110: 126-44.

[62] Yendadast A, Danjou IK, Oie E, et al. Systemic inflammation in heart failure—the whys and wherefores. Heart Fail Rev 2006; 11: 83-92.

[63] Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res 2012; 110: 159-73.

[64] Jenkins CM, Cedars A, Gross RW. Eicosanoid signalling pathways in the heart. Cardiovasc Res 2009; 82: 240-9.
[91] Chan P, Tomlinson B. Antioxidant effects of Chinese traditional medicine: focus on trilinolein isolated from the Chinese herb sanchi (Panax pseudoginseng). J Clin Pharmacol 2000; 40: 457-61.

[92] Tu Q, Wang R, Ding B, et al. Protective and antioxidant effect of Danshen polysaccharides on cerebral ischemia/reperfusion injury in rats. Int J Biol Macromol 2013; 60: 268-71.

[93] Liu J, Zhao J, Dai Z, et al. A pair of new antioxidant phenolic acid stereoisomers isolated from danshen injection (lyophilized powder). Molecules 2014; 19: 1786-94.

[94] Bernatoniene J, Masteikova R, Majiene D, et al. Free radical-scavenging activities of Crataegus monogyna extracts. Medicina (Kaunas) 2008; 44: 706-12.

[95] Zhou YC, Liu B, Li YJ, Xiao J, Deng SB, She Q, et al. Bax translocation and prolongs cardiac cold preservation time in protein is induced by hypoxia. Proc Natl Acad Sci USA 2000; 97: 305.

[96] Huang J, Nakamura K, Ito Y, et al. Effects of polysaccharides extracted from zhu zi shen (Rhizoma panaxis majoris) on oxidative stress and hemodynamics in rats with adriamycin-induced chronic heart failure. J Tradit Chin Med 2011; 31: 235-40.

[97] Li J, Ge R, Tang L, et al. Protective effects of farrerol against hydrogen-peroxide-induced apoptosis in human endothelium-derived EA.hy926 cells. J Ethnopharmacol 2012; 143: 100-8.

[98] Chen T, Hu YQ, Deng LR, et al. Effects of polysaccharides extracted from zhu zi shen (Rhizoma panaxis majoris) on oxidative stress and hemodynamics in rats with adriamycin-induced chronic heart failure. J Tradit Chin Med 2011; 31: 235-40.

[99] Li J, Ge R, Tang L, et al. Protective effects of farrerol against hydrogen-peroxide-induced apoptosis in human endothelium-derived EA.hy926 cells. J Ethnopharmacol 2012; 143: 100-8.

[100] Chen T, Hu YQ, Deng LR, et al. Effects of polysaccharides extracted from zhu zi shen (Rhizoma panaxis majoris) on oxidative stress and hemodynamics in rats with adriamycin-induced chronic heart failure. J Tradit Chin Med 2011; 31: 235-40.

[101] Kim NH, Kang PM. Apoptosis in cardiovascular diseases: mechanism and clinical implications. Korean Circ J 2010; 40: 299-305.

[102] Huang J, Nakamura K, Ito Y, et al. Bcl-xL gene transfer inhibits Bax translocation and prolongs cardiac cold preservation time in rats. Circulation 2005; 112: 76-83.

[103] Imahashi K, Schneider MD, Steenbergen C, et al. Transgenic expression of Bcl-2 modulates energy metabolism, prevents cytosolic acidification during ischemia, and reduces ischemia/reperfusion injury. Circ Res 2004; 95: 734-41.

[104] Hochhauser E, Kivity S, Offen D, et al. Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice. Am J Physiol Heart Circ Physiol 2003; 284: H2351-9.

[105] Bruck RK. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 2000; 97: 9082-7.

[106] Xiao J, Deng SB, She Q, et al. Traditional Chinese medicine Qili qiangxin inhibits cardiomyocyte apoptosis in rats following myocardial infarction. Exp Ther Med 2015; 10: 1817-23.

[107] Zhou YC, Liu B, Li YJ, et al. Effects of ‘buyang huwuo’ decoction on ventricular remodeling and differential protein profile in a rat model of myocardial infarction. Evid Based Complement Alternat Med 2012; 2012: 385247.

[108] Qings LS, Xue Y, Zheng Y, et al. Ligand fishing from Dioscorea nipponica extract using human serum albumin functionalized magnetic nanoparticles. J Chromatogr A 2010; 1217: 4663-8.

[109] Qin J, Kang Y, Xu Z, et al. Dioscin prevents the mitochondrial apoptosis and attenuates oxidative stress in cardiac H9c2 cells. Drug Res (Stuttg) 2014; 64: 47-52.

[110] Chen S, Liu J, Liu X, et al. Panax notoginseng saponins inhibit ischemia-induced apoptosis by activating P38/Akt pathway in cardiomyocytes. J Ethnopharmacol 2011; 137: 263-70.

[111] Chen Y, Tang Y, Xiang Y, et al. Shengmai injection improved doxorubicin-induced cardiomyopathy by alleviating myocardial endoplasmic reticulum stress and caspase-12 dependent apoptosis. Biomed Res Int 2015; 2015: 952671.

[112] Xing YL, Zhou Z, Agula, et al. Protocatechuic aldehyde inhibits lipopolysaccharide-induced human umbilical vein endothelial cell apoptosis via regulation of caspase-3. Phytheros Res 2012; 26: 1344-41.

[113] Zhao Y, Ransom JF, Li A, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007; 129: 303-17.

[114] Shimmizu N, Yoshiyama M, Omuta T, et al. Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res 1998; 38: 116-24.

[115] Saurin AT, Martin JL, Heads RJ, et al. The role of differential activation of p38 mitogen-activated protein kinase in preconditioned ventricular myocytes. FASEB J 2000; 14: 2237-46.

[116] Zhang Y, Zhang L, Chu W, et al. Tanshinone IIIA inhibits miR-1 expression through p38 MAPK signal pathway in post-infarction rat cardiomyocytes. Cell Physiol Biochem 2010; 26: 991-8.

[117] Azevedo PS, Minicucci MF, Santos PP, et al. Energy metabolism in cardiac remodeling and heart failure. Cardiol Rev 2013; 21: 135-40.

[118] Robinson E, Grieve DJ. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol Ther 2009; 122: 246-63.

[119] Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.

[120] Wang Y, Li C, Wang Q, et al. Danqi Pill regulates lipid metabolism disorder induced by myocardial ischemia through FAP7/CPTI pathway. BMC Complement Altern Med 2015; 15: 28.

[121] Fang DL, Zhao HP, Pan CS, et al. QiShenYiQi pills, a compound chinese medicine, ameliorates doxorubicin-induced myocardial structure damage and cardiac dysfunction in rats. Evid Based Complement Alternat Med 2013; 2013: 480597.

[122] Chen JR, Wei J, Wang LY, et al. Cardioprotection against ischemia/reperfusion injury by QiShenYiQi Pill(R) via ameliorate of multiple mitochondrial dysfunctions. Drug Devel Ther 2015; 9: 1051-66.

[123] Chen YY, Li Q, Pan CS, et al. QiShenYiQi Pills, a compound in Chinese medicine, protects against pressure overload-induced cardiac hypertrophy through a multi-component and multi-target mode. Sci Rep 2015; 5: 11802.

[124] Guo N, Yang D, Wang X, et al. Metabolic study of chronic heart failure and effects of Chinese herbal decoction in rats. J Chromatogr A 2014; 1362: 89-101.

[125] Li S, Xu H. Integrative Western and chinese medicine on coronary heart disease: where is the orientation? Evid Based Complement Alternat Med 2013; 2013: 459264.

[126] Zhao J, Jiang P, Zhang W. Molecular networks for the study of TCM pharmacology. Brief Bioinform 2010; 11: 417-30.

[127] Tao W, Xu X, Wang X, et al. Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix curcumae formula for application to cardiovascular disease. J Ethnopharmacol 2013; 145: 1-10.

[128] Li S, Zhang B, Zhang N. Network target for screening synergistic drug combinations with application to traditional Chinese medicine. BMC Syst Biol 2011; 5 (Suppl 1): S10.

[129] Zhao S, Li S. Network-based relating pharmacological and genomic spaces for drug target identification. PLoS One 2010; 5: e17164.

[130] Li X, Wu L, Liu W, et al. A network pharmacology study of Chinese medicine QiShenYiQi to reveal its underlying multi-component, multi-target, multi-pathway mode of action. PLoS One 2014; 9: e95004.